recent
identifi
broadli
neutral
antibodi
bnab
show
great
potenti
clinic
intervent
infect
howev
resist
strain
may
impos
substanti
challeng
report
identif
character
panel
strain
broad
potent
resist
larg
number
bnab
particularli
target
site
sitedirect
mutagenesi
reveal
sever
key
epitop
mutat
facilit
resist
locat
inner
domain
loop
resist
larg
correl
bind
affin
antibodi
envelop
trimer
express
cell
surfac
result
therefor
demonstr
exist
broadli
resist
strain
neutral
antibodi
treatment
strategi
base
bnab
must
overcom
resist
achiev
optim
clinic
outcom
recent
identifi
broadli
neutral
antibodi
bnab
show
great
potenti
clinic
intervent
infect
among
bnab
isol
date
target
abund
thoroughli
studi
disrupt
crucial
step
viral
interact
cellular
receptor
molecul
despit
superior
potenc
breadth
bnab
fail
neutral
small
signific
portion
pseudotyp
viru
panel
report
identif
character
panel
strain
broad
potent
resist
larg
number
bnab
particularli
target
resist
larg
attribut
mutat
residu
within
epitop
steric
hindranc
impos
bulki
sidechain
glycan
shield
mutat
residu
larg
correl
reduc
bind
avid
antibodi
quaternari
trimer
envelop
protein
express
plo
pathogen
http
doisurfac
transfect
cell
treatment
strategi
base
bnab
therefor
must
overcom
resist
achiev
optim
clinic
outcom
recent
scientif
advanc
identifi
grow
number
broadli
neutral
antibodi
bnab
human
immunodefici
viru
type
provid
promis
candid
prevent
treatment
compar
bnab
isol
earlier
studi
bnab
demonstr
broader
potent
activ
global
panel
display
impress
safeti
efficaci
profil
therapeut
applic
number
anim
model
human
clinic
trial
result
also
offer
opportun
tailor
antibodi
maxim
prevent
treatment
potenti
broadli
speak
bnab
recogn
six
major
vulner
site
envelop
glycoprotein
site
apex
glycan
fusion
peptid
fp
subunit
interfac
membran
proxim
extern
region
mper
bnab
neutral
block
viral
entri
target
cell
although
addit
effector
function
like
play
particularli
context
vivo
infect
clinic
applic
among
bnab
isol
date
target
abund
thoroughli
studi
disrupt
first
crucial
step
viral
interact
cellular
receptor
step
trimer
envelop
glycoprotein
compos
bind
target
cell
receptor
either
coreceptor
trigger
cascad
conform
chang
fuse
viral
envelop
target
membran
releas
viral
genom
cell
two
dozen
bnab
isol
date
number
like
grow
advent
specif
highthroughput
techniqu
isol
antibodiesfor
instanc
prototyp
close
rel
effect
neutral
panel
divers
pseudotyp
virus
isol
cladeb
infect
individu
recent
isol
bnab
shown
similar
even
enhanc
potenc
breadth
compar
bnab
classifi
two
group
base
mode
recognit
heavi
chain
characterist
class
class
structur
bnab
recogn
residu
within
inner
domain
loop
bind
loop
region
loop
also
impact
recognit
particularli
context
quaternari
trimer
envelop
protein
primari
mechan
neutral
mimic
compet
receptorto
bind
therebi
prevent
bound
trimer
transit
subsequ
step
requir
membran
fusion
although
evid
indic
differ
fine
detail
process
despit
superior
potenc
breadth
bnab
fail
neutral
small
signific
portion
pseudotyp
viru
panel
instanc
unabl
neutral
test
virus
resist
strain
isol
patient
infect
subtyp
b
subtyp
c
furthermor
report
show
strain
emerg
anim
model
human
clinic
trial
indic
resist
viru
broadli
resist
antibodi
plo
pathogen
http
introduct
strain
occur
natur
select
antibodi
treatmenta
clinic
trial
bnab
underway
resist
virus
expect
emerg
identif
character
resist
strain
paramount
understand
molecular
basi
resist
ultim
develop
strategi
effect
control
studi
report
identif
character
panel
strain
broad
potent
resist
larg
number
bnab
particularli
target
hereaft
refer
resist
clone
resist
panel
bnab
clone
within
panel
deriv
envelop
sequenc
collect
acut
chronic
infect
patient
well
earlier
literatur
report
system
analysi
resist
clone
reveal
critic
residu
within
well
molecular
featur
confer
broad
resistanceresist
either
due
mutat
residu
steric
hindranc
impos
bulki
sidechain
glycan
shield
mutat
residu
level
resist
larg
correl
reduc
bind
avid
antibodi
quaternari
trimer
envelop
protein
express
surfac
transfect
cell
result
highlight
exist
strain
broadli
resist
bnab
infect
populationtreat
strategi
base
bnab
would
need
overcom
resist
achiev
optim
clinic
outcom
previous
character
larg
number
fulllength
sequenc
infect
individu
china
wide
distribut
among
three
major
genet
cluster
subtyp
subtyp
b
subtyp
c
pseudovirus
bear
env
expos
subtypespecif
plasma
pool
bnab
observ
substanti
differ
neutral
sensit
mani
clone
resist
one
bnab
includ
known
high
potenc
breadth
divers
outsid
chinasom
select
global
panel
env
refer
clone
nihaid
reagent
program
cat
base
uniqu
genotyp
phenotyp
featur
bnab
sinc
identifi
sought
reevalu
resist
clone
larger
array
antibodi
particular
focu
target
tabl
six
clone
deriv
chines
panel
show
variabl
broad
resist
potent
bnab
class
famili
tabl
instanc
resist
bnab
inhibitori
concentr
ic
less
cognat
deriv
patient
resist
equal
bnab
evad
bnab
testedth
resist
level
rose
neutral
stringent
defin
ic
less
tabl
broadli
resist
clone
also
identifi
nonchines
panel
tabl
right
panel
three
verifi
select
indepth
mutat
analys
demonstr
resist
test
resist
tabl
left
panel
furthermor
clone
equal
resist
bnab
target
env
site
subunit
interfac
fusion
peptid
mper
tabl
note
clone
deriv
patient
acut
chronic
infect
none
receiv
intervent
relat
bnabsnot
among
previous
publish
first
column
neutral
breadth
compar
percentag
virus
neutral
tabl
larg
panel
databas
calcul
base
data
catnap
databas
overal
averag
refer
percentag
antibodi
neutral
resist
strain
separ
accord
type
number
repres
estim
mean
ic
nonchines
clone
except
isol
acut
earli
infect
tabl
right
panel
find
indic
broad
resist
natur
occur
also
transmiss
capabl
replic
newli
infect
patient
identifi
residu
potenti
confer
broad
resist
conduct
compar
sequenc
analysi
resist
sensit
strain
avail
hiv
sequenc
databas
http
wwwhivlanlgov
publish
literatur
broad
resist
defin
strain
resist
least
bnab
test
ic
sensit
strain
suscept
least
ic
less
criteria
identifi
total
broadli
resist
strain
refer
resist
panel
bnab
includ
nine
select
thorough
analysi
hand
sensit
strain
divers
genet
geograph
background
sequenc
align
sequenc
standard
sensit
strain
jrfl
reveal
substanti
differ
resist
sensit
strain
fig
notabl
chang
inner
domain
loop
region
critic
recognit
bnab
resist
strain
also
alter
potenti
nglycosyl
site
particularli
region
fig
use
program
weblogo
quantifi
alter
residu
epitop
sequenc
disproport
repres
among
resist
sensit
strain
identifi
databas
fig
residu
respectivelyin
particular
potenti
nglycosyl
site
posit
previous
shown
conferresist
class
antibodi
increas
proport
among
sensit
strain
among
resist
one
result
suggest
multipl
residu
may
link
act
unison
confer
resist
although
role
residu
like
variabl
depend
antibodi
actual
strain
recognizea
mani
residu
locat
within
antibodi
contact
region
observ
resist
like
result
reduc
antibodi
bind
either
due
mutat
residu
steric
hindranc
impos
mutat
residu
studi
role
abovement
residu
confer
resist
use
sitedirect
mutagenesi
gener
total
mutant
accord
consensu
sensit
sequenc
highlight
fig
mutant
envelop
includ
singl
doubl
tripl
quadrupl
substitut
along
variou
possibl
combin
thereofpseudovirus
bear
mutant
envelop
test
sensit
repres
antibodi
class
predict
sequenc
analysi
mutat
signatur
residu
sensit
tabl
neutral
activ
except
two
instanc
singl
residu
fulli
restor
sensit
rest
requir
multipl
substitut
one
contact
regionsfor
exampl
requir
tripl
doubl
doubl
tripl
doubl
tripl
quadrupl
doubl
tripl
quadrupl
doubl
tripl
substitut
restor
sensit
measur
ic
less
tabl
left
column
neutral
activ
furthermor
differ
set
tripl
substitut
requir
restor
sensit
tabl
left
column
neutral
activ
furthermor
impact
substitut
differ
across
differ
strain
exampl
doubl
mutat
posit
fail
restor
sensit
measur
actual
contact
residu
indic
align
sequenc
color
dot
repres
singl
contact
residu
red
bnab
class
blue
class
residu
differ
sequenc
indic
color
repres
differ
biochem
properti
green
polar
blue
basic
red
acid
black
hydrophob
purpl
n
q
residu
dot
repres
ident
residu
dash
repres
gap
introduc
preserv
align
b
identif
signatur
substitut
quantit
comparison
broadli
resist
strain
sensit
one
use
program
weblogo
total
sensit
strain
neutral
identifi
report
research
signatur
substitut
disproport
repres
among
resist
sensit
strain
highlight
indic
locat
color
scheme
signatur
substitut
residu
number
base
sequenc
number
neutral
activ
repres
estim
mean
valu
ic
ic
deriv
least
three
independ
experi
color
scheme
tabl
number
bind
activ
repres
mean
variat
estim
gmfi
valu
least
three
independ
experi
increas
ic
less
tabl
left
column
neutral
activ
furthermor
doubl
mutat
also
differ
effect
spite
share
origin
fact
former
fulli
convert
latter
remain
resist
tabl
left
column
neutral
activ
result
support
hypothesi
multipl
mutat
act
concert
confer
resist
although
specif
residu
requir
contribut
vari
strain
strainit
need
note
singl
substitut
suffici
improv
sensit
revert
resist
clone
carri
mutat
particularli
true
resist
less
tabl
left
column
neutral
activ
role
nglycosyl
therefor
differ
resist
differ
antibodiesster
hindranc
particular
glycosyl
may
hinder
access
cognat
epitop
less
virtual
neglig
among
class
antibodi
test
stand
neutral
wild
type
mutant
strain
carri
signatur
substitut
except
tabl
left
column
neutral
activ
antibodi
group
remain
unabl
neutral
mutat
clone
except
exampl
among
mutant
tabl
left
column
neutral
activ
signatur
mutat
therefor
contribut
littl
class
antibodi
factor
mutat
beyond
test
angl
antibodi
approach
epitop
like
play
signific
role
lastli
mutant
strain
show
drastic
chang
sensit
antibodi
ibalizumab
suggest
signatur
mutat
alter
interact
envelop
receptor
exampl
mutat
greatli
reduc
complet
abolish
neutral
sensit
ibalizumab
consist
previou
report
glycan
crucial
ibalizumab
recognit
signific
reduct
ibalizumab
neutral
activ
also
occur
mani
mutant
clone
highlight
tabl
left
column
neutral
activ
signatur
substitut
appear
alter
sensit
complet
convers
sensit
resist
observ
mutant
opposit
convers
also
found
mani
mutant
deriv
highlight
yellow
green
tabl
left
column
neutral
activ
howev
wildtyp
mutant
strain
maintain
depend
receptor
coreceptor
entri
except
case
coreceptor
alon
suffici
albeit
significantli
reduc
entri
effici
vs
tabl
right
column
receptor
usag
consist
previou
report
fit
cost
associ
escap
antibodi
found
compromis
entri
potenti
broadli
resist
strain
howev
remain
show
appreci
differ
compar
maxim
convert
sensit
counterpart
tabl
receptor
usag
taken
togeth
result
highlight
signatur
substitut
within
antibodi
contact
site
critic
determin
viral
strain
resist
phenotyp
particularli
true
class
less
class
antibodi
signatur
substitut
also
appear
alter
interact
envelop
molecul
affect
viral
entri
effici
highlight
structur
plastic
function
divers
facilit
bind
cellular
receptor
entri
target
cell
studi
potenti
mechan
signatur
substitut
restor
antibodi
sensit
first
compar
effect
antibodi
bind
envelop
trimer
cell
transfect
total
mutat
envelop
clone
express
trimer
cell
surfac
stain
separ
togeth
appropri
background
control
mocktransfect
cell
envelopetransfect
cell
stain
secondari
conjug
antibodi
gate
strategi
properli
adjust
accord
control
geometr
mean
fluoresc
intens
gmfi
variat
estim
base
repeat
experi
test
antibodi
tabl
bind
activ
fig
consist
neutral
studi
improv
antibodi
bind
predominantli
occur
clone
multipl
substitut
one
contact
region
exampl
found
enhanc
bind
activ
toward
doubl
tripl
mutant
doubl
mutant
tripl
mutant
doubl
tripl
mutant
tabl
bind
activ
particular
tripl
mutat
also
led
enhanc
bind
singl
mutat
trimer
also
improv
bind
test
antibodi
demonstr
enhanc
bind
either
tabl
bind
activ
suggest
glycan
posit
may
contribut
least
partial
resist
clone
howev
singl
mutat
within
predict
contact
site
restor
neutral
activ
measur
chang
bind
identifi
perhap
surpris
mutat
may
contribut
substanti
bind
energi
overal
interact
role
individu
residu
also
expect
vari
depend
envelop
context
note
bind
enhanc
larg
proport
mutant
trimer
impact
activ
rel
smaller
highest
improv
found
trimer
quadrupl
mutat
tabl
bind
activ
next
conduct
correl
analysi
cell
surfac
bind
neutral
activ
fig
data
test
antibodi
combin
found
signific
direct
correl
cell
surfac
bind
neutral
activ
ic
ic
p
spearman
r
fig
individu
antibodi
signific
correl
cell
surfac
bind
neutral
activ
also
identifiedtaken
togeth
find
support
idea
major
mutat
studi
restor
neutral
sensit
larg
enhanc
bind
antibodi
respect
target
epitop
steric
disrupt
like
play
predomin
role
case
remov
glycan
posit
improv
bind
neutral
analyz
substitut
studi
act
restor
antibodi
sensit
introduc
sever
residu
combin
envelop
clone
jrfl
strain
sensit
test
antibodi
hypothes
incorpor
resistanceconf
substitut
envelop
sensit
strain
convert
resist
phenotyp
test
combin
signatur
substitut
match
introduc
jrfl
envelop
strain
alter
match
extra
serin
residu
ad
region
convert
asparagin
n
posit
potenti
glycosyl
sitea
shown
fig
pseudovirus
bear
mutat
jrfl
envelop
significantli
improv
resist
bnab
class
substitut
appear
effect
confer
resist
demonstr
significantli
enhanc
resist
respect
measur
ic
previous
discuss
surpris
sinc
expect
envelop
clone
requir
differ
set
substitut
confer
resist
rel
role
substitut
may
vari
differ
envelop
context
given
jfrl
model
viru
sensit
test
antibodi
addit
substitut
may
need
gener
broader
level
resist
interestingli
clone
fulli
resist
deriv
inadvert
becam
highli
sensit
ibalizumabth
addit
addit
glycan
posit
may
provid
structur
support
requir
ibalizumab
recognit
similar
reason
could
also
explain
improv
sensit
ibalizumabhowev
sensit
remain
uncertain
lastli
entri
practic
mutant
jrfl
variant
target
cell
remain
depend
receptor
coreceptor
except
whose
entri
effici
reduc
approxim
rel
origin
jrfl
vs
fig
receptor
usag
supersit
target
antibodi
compos
multipl
area
includ
loop
loop
loop
outer
domain
exit
loop
small
patch
inner
domain
fig
signatur
mutat
confer
resist
site
antibodi
aros
region
fig
explain
structur
basi
substitut
analyz
resistancerel
mutat
use
prefus
close
env
structur
antibodi
bound
pdb
id
dock
complex
align
outer
domain
pdb
id
comparison
epitop
class
antibodi
indic
signific
overlap
center
loop
outer
domain
exit
loop
fig
analysi
contact
residu
indic
inner
domain
residu
conserv
made
salt
bridg
cdr
residu
fig
note
ly
glu
mutat
occur
posit
resist
strain
fig
loop
residu
highli
conserv
receptor
usag
base
cell
line
also
indic
data
present
mean
least
three
independ
experi
color
scheme
use
ident
tabl
either
asp
asn
conserv
accord
lanl
databas
form
hydrogen
bond
conserv
trp
cdr
class
antibodi
mutat
residu
abolish
critic
hydrogen
bond
fig
probabl
contribut
resist
phenotyp
strain
convers
revert
confer
sensit
class
antibodi
tabl
disrupt
key
salt
bridg
hydrogen
bond
antibodi
appar
one
factor
contribut
resist
phenotyp
hand
hydrogen
bond
conserv
cdr
class
antibodi
made
loop
residu
main
chain
atom
seem
independ
sidechain
mutat
howev
mutat
amino
acid
bulkier
side
chain
locat
leu
glu
occur
strain
caus
steric
hindranc
class
antibodi
henc
confer
resist
fig
structur
data
indic
residu
short
side
chain
ala
prefer
sensit
strain
ala
thr
val
mutat
provid
steric
hindranc
antibodi
bind
also
occur
sever
posit
residu
loop
residu
outer
domain
exit
loop
residu
fig
revert
strain
thr
conserv
restor
sensit
tabl
chang
conserv
bulkier
residu
occur
resist
strain
fig
addit
glycosyl
posit
loop
also
made
antibodi
bind
difficult
fig
revert
ala
made
sensit
class
antibodi
howev
remov
glycan
posit
reduc
sensit
ibalizumab
unlik
class
antibodi
primarili
use
domain
bind
less
sensit
signatur
substitut
especi
mutat
tabl
comparison
antibodi
footprint
env
indic
epitop
slightli
distant
loop
loop
shift
toward
trimer
apex
despit
signific
overlap
epitop
class
antibodi
fig
consequ
sever
critic
contact
residu
class
antibodi
loop
residu
loop
residu
longer
interact
though
mainchain
atom
loop
residu
make
hydrogen
bound
residu
g
along
side
cdr
mutat
residu
bulkier
side
chain
creat
steric
clash
therefor
mutat
confer
resist
contrast
outer
domain
exit
loop
residu
lie
underneath
cdr
make
hydrogen
bond
chr
mainchain
atom
model
indic
mutat
glycin
posit
would
result
steric
clash
thu
confer
resist
fig
consist
observ
resist
revert
gli
essenti
restor
sensit
tabl
therefor
even
though
class
antibodi
target
gener
area
slight
differ
recognit
give
differ
sensit
resist
mutat
collect
signatur
mutat
confer
resist
antibodi
locat
multipl
region
within
supersit
mechanist
mutat
could
act
abolish
hydrogen
bond
andor
salt
bridg
shown
mutat
posit
nonlysin
residu
posit
nonasnasp
residu
mutat
could
also
act
impos
steric
hindranc
antibodi
contact
observ
mutat
amino
acid
bulkier
side
chain
ala
posit
thr
posit
gli
posit
alter
potenti
glycosyl
site
anoth
mode
resist
observ
mani
resist
strain
glycosyl
posit
note
class
antibodi
well
class
antibodi
use
canon
cdr
recognit
could
toler
differ
resist
mutat
potenti
due
distinct
bind
mode
new
gener
bnab
emerg
promis
candid
clinic
intervent
infectionhowev
exist
emerg
resist
would
impos
substanti
challeng
optim
clinic
outcom
studi
identifi
character
divers
clone
resist
larg
number
bnab
particularli
target
resist
panel
bnab
clone
repres
small
signific
proport
larg
envelop
collect
acut
chronic
infect
patient
well
literatur
report
importantli
clone
isol
patient
divers
ethnic
geograph
origin
variou
stage
diseas
progress
transmiss
sitedirect
mutagenesi
structur
analysi
reveal
key
residu
within
bnab
epitop
molecular
featur
confer
resist
resist
larg
correl
reduc
bind
avid
antibodi
quaternari
trimer
envelop
protein
express
cell
surfac
although
steric
hindranc
bulki
sidechain
glycan
proxim
epitop
also
detectedthes
find
agreement
observ
evid
natur
occur
resist
antibodiestreat
strategi
util
antibodi
would
need
overcom
resist
achiev
optim
clinic
outcom
sever
find
studi
worth
highlight
first
strain
resist
bnab
appear
preval
expect
among
fulllength
clone
previous
character
approxim
found
broadli
resist
possibl
mani
clone
isol
chronic
stage
infect
diverg
swarm
strain
present
acut
earli
stage
extent
result
reminisc
find
human
clinic
trial
bnab
monotherapi
regimen
evalu
chronic
patient
wherebi
less
sensit
resist
strain
frequent
detect
rebound
viral
popul
howev
mean
indic
broadli
resist
strain
aris
acut
earli
phase
infect
fact
among
broadli
resist
strain
highlight
came
acut
earli
infect
patient
tabl
although
preval
remain
uncertain
exist
impli
success
compet
wildtyp
clone
transmit
uninfect
individu
regard
combin
therapi
bnab
target
one
vulner
site
envelop
would
efficaci
approach
monotherapi
similar
lesson
alreadi
learn
develop
antiretrovir
drug
combin
therapyi
requir
protect
resist
achiev
sustain
suppress
viral
replic
ultim
treatment
strategi
integr
antiretrovir
drug
bnab
like
maxim
potenti
class
secondli
found
multipl
substitut
one
contact
region
target
antibodi
requir
fulli
restor
antibodysensit
phenotyp
case
contribut
residu
overal
resist
vari
antibodi
highlight
complex
natur
immun
system
evas
emerg
spread
regard
broadli
resist
strain
like
product
continu
viral
evolut
immun
pressur
rather
singl
instantan
event
fact
key
contact
site
residu
respons
broad
resist
frequent
share
among
less
sensit
strain
identifi
natur
infect
well
anim
model
bnab
monotherapi
human
trial
exampl
nearli
variant
found
recent
plasma
sampl
origin
donor
resist
strain
previous
identifi
chronic
infect
patient
similar
found
current
studi
mutat
respons
resist
also
confin
area
residu
loop
potenti
nlink
glycosyl
site
residu
region
analys
rebound
virus
human
mice
rhesu
macaqu
model
antibodi
monotherapi
also
reveal
mutat
loop
region
particular
human
monotherapi
trial
antibodi
reveal
signific
polymorph
shift
plasma
rna
popul
found
abovement
posit
fig
due
preselect
particip
shift
profound
trial
notic
increas
frequenc
glutam
acid
e
posit
possibl
disrupt
salt
bridg
aspart
acid
cdr
class
antibodi
well
aspart
acid
posit
treatment
fig
emerg
asparagin
residu
n
posit
also
found
treatment
fig
similarli
emerg
aspart
acid
posit
glutam
acid
e
asparagin
n
posit
also
identifi
second
trial
fig
howev
shift
residu
frequenc
quit
minim
trial
although
high
degre
polymorph
undoubtedli
provid
rich
genet
base
futur
select
fig
collect
result
suggest
broadli
resist
strain
identifi
aros
select
pressur
immun
respons
natur
infect
bnab
treatment
final
none
chines
patient
highli
unlik
nonchines
patient
studi
develop
bnab
resist
virus
identifi
unlik
result
select
forc
equival
bnab
studi
exactli
broadli
resist
antibodi
select
mutat
emerg
first
place
therefor
remain
unclear
believ
broadli
resist
strain
natur
occur
emerg
like
result
combin
random
mutat
event
due
errorpron
natur
revers
transcriptas
immun
select
viral
escap
major
mechan
appear
includ
reduct
antibodi
bind
contact
residu
increas
steric
obstruct
impos
bulki
sidechain
glycansat
mutat
residuesa
pandem
continu
evolv
particularli
antibodi
enter
clinic
studi
resist
strain
expect
aris
overcom
resist
optim
clinic
outcom
potent
broadli
effect
antibodi
need
either
isol
antibodi
except
neutral
activ
patient
engin
exist
antibodi
bior
trispecif
combin
combin
class
cdr
antibodi
may
also
benefici
altern
develop
therapeut
antibodi
cocktail
due
differ
sensit
resist
mutat
envelop
clone
isol
infect
patient
previous
report
obtain
dr
john
mascola
vaccin
research
center
nih
usa
dr
feng
gao
jilin
univers
chinaa
total
antibodi
recogn
bind
site
apex
glycan
induc
subunit
interfac
fusion
peptid
fp
membran
proxim
extern
region
mper
use
evalu
neutral
sensit
pseudovirus
bear
abovement
envelop
clone
antibodi
kindli
provid
dr
john
mascola
vaccin
research
center
nih
michel
nussenzweig
rockefel
univers
barton
hayn
duke
univers
denni
burton
scripp
research
institut
wayn
koff
human
vaccin
project
antibodi
crystal
structur
publish
sequenc
variabl
gene
synthes
clone
human
express
vector
provid
michel
nussenzweig
rockefel
univers
fulllength
express
cotransfect
cell
atcc
pair
heavyand
lightchain
plasmid
purifi
affin
chromatographi
use
protein
column
thermo
scientif
follow
manufactur
instruct
antibodi
concentr
determin
use
bca
protein
assay
kit
thermo
scientif
ibalizumab
antibodi
second
cellular
domain
human
molecul
kindli
provid
dr
david
ho
aaron
diamond
aid
research
center
rockefel
univers
solubl
encod
first
two
domain
link
fc
express
purifi
quantifi
describ
antibodi
total
mutant
envelop
clone
gener
use
sitedirect
mutagenesi
kit
agil
confirm
sequenc
mutant
envelop
includ
singl
doubl
tripleand
quadrupl
substitut
well
variou
possibl
combin
thereof
mutant
jrfl
envelop
contain
multipl
substitut
deriv
also
gener
confirm
sequenc
pseudovirus
bear
wildtyp
mutant
envelop
gener
cotransfect
cell
env
express
vector
viral
backbon
plasmid
describ
previous
pseudoviruscontain
supernat
collect
hour
post
transfect
viral
titer
measur
luciferas
activ
rel
light
unit
rlu
brightglo
luciferas
assay
system
promega
bioscienc
california
usa
supernat
aliquot
store
use
neutral
assay
perform
ad
median
tissu
cultur
infecti
dose
pseudoviru
serial
dilut
purifi
antibodi
start
mixtur
dispens
plate
triplic
incub
h
cell
ad
cultur
maintain
addit
luciferas
activ
measuredneutr
activ
measur
reduct
luciferas
activ
compar
control
fiftyand
eighti
percentmaxim
inhibitori
concentr
ic
ic
concentr
requir
inhibit
infect
compar
control
calcul
use
doseresponseinhibit
model
hill
slope
equat
graphpad
prism
graphpad
softwar
usa
ic
ic
valu
report
virus
obtain
catanp
http
wwwhivlanlgovcomponentssequencehivneutr
protein
sequenc
resist
sensit
strain
download
lo
alamo
hiv
sequenc
databas
wwwhivlanlgov
align
subtyp
b
refer
sequenc
jrfl
use
bioedit
http
wwwmbioncsuedu
bioeditbioedithtml
frequenc
differ
residu
posit
analyz
sequenc
logo
gener
use
weblogo
tool
http
weblogothreeplusonecom
antibodi
bind
envelop
trimer
cell
surfac
total
hek
cell
seed
round
cell
cultur
dish
incub
cell
transfect
total
env
express
plasmid
mix
pei
optimem
gibco
usa
incub
hour
cell
harvest
distribut
roundbottom
tissu
cultur
plate
individu
stain
reaction
stain
reaction
cell
wash
thrice
stain
buffer
pb
heatinactiv
fb
gibco
usa
mm
edta
cell
stain
minut
stain
buffer
primari
antibodi
room
temperatur
wash
thrice
stain
buffer
cell
stain
pe
label
antihuman
igg
secondari
antibodi
rabbit
antihuman
iggp
santa
cruz
dilut
stain
buffer
minut
room
temperatur
follow
three
wash
stain
buffer
cell
resuspend
analyz
facscalibur
instrument
bd
bioscienc
usa
use
flowjo
softwar
flowjo
usa
appropri
neg
control
includ
mocktransfect
cell
secondari
conjug
antibodi
label
envtransduc
cell
background
control
secondari
antibodi
irrelev
antibodi
target
receptor
bind
domain
middl
east
respiratori
syndrom
coronaviru
antibodi
recogn
loop
use
primari
posit
control
cell
line
express
human
cell
line
express
human
use
evalu
depend
viral
entri
moleculesthey
kindli
provid
dr
cecilia
chengmay
aaron
diamond
aid
research
center
rockefel
univers
briefli
undilut
viral
stock
incub
medium
contain
cell
cultur
fed
fresh
complet
medium
follow
day
viru
entri
measur
day
later
determin
luciferas
activ
cell
lysat
rel
light
unit
rlu
brightglo
luciferas
assay
system
promega
bioscienc
california
usa
env
structur
complex
structur
core
complex
antibodi
superpos
outer
domain
region
residu
mutat
model
use
mutagenesi
function
pymol
antibodyantigen
interact
includ
hydrogen
bond
salt
bridg
identifi
use
pdbepisa
http
wwwebi
acukmsdsrvprotintpistarthtml
geometr
mean
fluoresc
intens
gmfi
calcul
use
flowjo
softwar
flowjo
usa
pearson
correl
coeffici
pvalu
differ
gmfi
ic
ic
antibodi
calcul
use
graphpad
prism
graphpad
softwar
usa
